This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease | MicrobiomeTrials
← Back to trials NCT06944067
Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease Recruiting OBSERVATIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-06-24Est. Completion: 2030-04-10
Enrollment target: 50 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Sickle Cell Disease
'Sickle-shaped' anemia was first clinically described in the US in 1910, and the mutated heritable sickle hemoglobin mol…
Cleveland, United States Est. completion May 31, 2030
Sickle Cell Disease
The collection of human specimens from both patients and healthy volunteers is necessary for the development of laborato…
Bethesda, United States